Edit |   |
---|---|
Antigenic Specificity | PCSK9, Human (Bococizumab biosimilar) |
Clone | Bococizumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG2 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | FCM, IP, ELISA, Neut, FuncS |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human PCSK9 Recombinant Antibody (Bococizumab). Bococizumab (USAN, development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." |
Immunogen | n/a |
Other Names | Anti-PCSK9 Recombinant Antibody, Research Grade Bococizumab, Anti-Human PCSK9 Recombinant Antibody(Bococizumab), PF-04950615, RN-316, Antibody Drug Analogues, Monoclonal Antibody, YR1327, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1407495-02-6 |
Catalog # | YR1327 |
Price | please inquire |
Order / More Info | PCSK9, Human (Bococizumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |